The National Lung Matrix Trial of personalized therapy in lung cancer.

doi:10.1038/s41586-020-2481-8

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The National Lung Matrix Trial of personalized therapy in lung cancer.

Nature - 1 Jul 2020

Middleton Gary, Fletcher Peter, Popat Sanjay, Savage Joshua, Summers Yvonne, Greystoke Alastair, Gilligan David, Cave Judith, O'Rourke Noelle, Brewster Alison, Toy Elizabeth, Spicer James, Jain Pooja, Dangoor Adam, Mackean Melanie, Forster Martin, Farley Amanda, Wherton Dee, Mehmi Manita, Sharpe Rowena, Mills Tara C, Cerone Maria Antonietta, Yap Timothy A, Watkins Thomas B K, Lim Emilia, Swanton Charles, Billingham Lucinda

Abstract excerpt

The majority of targeted therapies for non-small-cell lung cancer (NSCLC) are directed against oncogenic drivers that are more prevalent in patients with light exposure to tobacco smoke1-3. As this group represents around 20% of all patients with lung cancer, the discovery of stratified medicine options for tobacco-associated NSCLC is a high priority. Umbrella trials seek to streamline the investigation of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Molecular Targeted Therapy

Share to Oncogenes

Share to Patient Selection

Share to Precision Medicine

Share to Smoke

Share to Triage

Source

Open in PubMed Open full text

Identifiers

PMID: 32669708
DOI: 10.1038/s41586-020-2481-8
PMCID: PMC7116732

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The National Lung Matrix Trial of personalized therapy in lung cancer.PMID 32669708Read ↗

Mastering the Complex Targeted Therapy for Non-small Cell Lung Cancer.Semantic proximity Read ↗

A state-of-the-art review of stratified medicine in cancer: towards a future precision medicine strategy in cancer.Semantic proximity Read ↗

Innovative Clinical Trials: The LUNG-MAP Study.Semantic proximity Read ↗

Personalizing therapy in advanced non-small cell lung cancer.Semantic proximity Read ↗

Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400Semantic proximity Read ↗

Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancer.Semantic proximity Read ↗

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2).Semantic proximity Read ↗

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.Semantic proximity Read ↗

The value of real-world evidence in supporting targeted therapies for patients with rare oncogenic drivers in mNSCLC.Semantic proximity Read ↗

Genetics and biomarkers in personalisation of lung cancer treatment.Semantic proximity Read ↗

DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.Semantic proximity Read ↗

Personalized therapy for lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.